ProShare Advisors
SPRY icon

ProShare Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

ProShare Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.7K Sell
11,325
-1,649
-13% -$14.2K ﹤0.01% 1788
2026
Q1 		$104K Sell
12,974
-2,165
-14% -$20.7K ﹤0.01% 1702
2025
Q4 		$176K Buy
15,139
+1,532
+11% +$14.9K ﹤0.01% 1757
2025
Q3 		$137K Sell
13,607
-1,303
-9% -$18.7K ﹤0.01% 1781
2025
Q2 		$260K Sell
14,910
-127
-0.8% -$1.83K ﹤0.01% 1547
2025
Q1 		$189K Sell
15,037
-3,426
-19% -$41.2K ﹤0.01% 1707
2024
Q4 		$195K Buy
18,463
+3,436
+23% +$48.1K ﹤0.01% 1895
2024
Q3 		$218K Buy
+15,027
New +$179K ﹤0.01% 1675
2024
Q2 		– Sell
-11,139
Closed -$114K – 1993
2024
Q1 		$114K Buy
11,139
+942
+9% +$7.02K ﹤0.01% 1798
2023
Q4 		$55.9K Buy
+10,197
New +$44.7K ﹤0.01% 1847

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

ProShare Advisors's SPRY Position: Q2 2026 in Review

ProShare Advisors reduced its ARS Pharmaceuticals (SPRY) stake by 13% in Q2 2026, selling an estimated $14.2K and leaving 11,325 shares worth $90.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1788.

ProShare Advisors first reported a position in SPRY in Q4 2023 and has held it in 10 quarters since. The position peaked at $260K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • ProShare Advisors held 11,325 shares of ARS Pharmaceuticals worth $90.7K as of Q2 2026.
  • ProShare Advisors sold 1,649 ARS Pharmaceuticals shares in Q2 2026, an estimated $14.2K.
  • ARS Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1788 holding.
  • ProShare Advisors first reported a position in ARS Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • ProShare Advisors's ARS Pharmaceuticals position peaked at $260K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.